FTC Reached Settlements With Major Pharmacy Managers

The Federal Trade Commission reached agreements with Express Scripts and CVS Caremark regarding insulin market practices.

Updated on Sept. 22, 2026 in Healthcare

Isometric editorial illustration of arranged glass medicine vials in a geometric grid on a laboratory surface, representing pharmaceutical regulation.
The Federal Trade Commission finalized settlement agreements with pharmacy benefit managers Express Scripts and CVS Caremark regarding insulin market rebate practices. AI Illustration. Upload story photo >

Live Poll

Do you believe current regulations on pharmacy benefit managers will lower your prescription drug costs?

The Federal Trade Commission has finalized settlement agreements with pharmacy benefit managers Express Scripts and CVS Caremark. These agreements address controversial practices involving rebates and incentives within the insulin market.

Why it matters

The Federal Trade Commission launched its investigation after determining that specific PBM practices contributed to higher drug costs for consumers. These settlements aim to impose new oversight on how intermediaries manage drug formularies and pharmacy payments.

The Federal Trade Commission reached agreements with two major pharmacy benefit managers to regulate rebate and incentive structures. The actual impact on drug prices remains uncertain as employers may seek alternative PBM offerings.

The players

Federal Trade Commission

This is the primary United States government agency responsible for protecting consumers and promoting competition.

Express Scripts

This organization operates as a major pharmacy benefit manager acting as an intermediary between insurance plans and drug manufacturers.

CVS Caremark

This entity serves as a pharmacy benefit management division that handles prescription drug coverage and pharmacy network administration.

The details

The settlements mandate specific changes to how pharmacy benefit managers handle drug formularies and dictate the flow of payments to pharmacies. They also establish new protocols for how savings are passed along to patients, though experts suggest these measures might be bypassed by alternative plan designs.

Timeline

  1. September 22, 2026: The Federal Trade Commission announced the settlement agreements.

Market Landscape

These settlements represent a formal conclusion to specific components of the Federal Trade Commission's PBM industry investigation. The move signals a broader regulatory effort to increase transparency in the opaque pharmacy benefit management sector.

Consumers may not see immediate relief in prescription drug prices due to these settlements. Employers may choose to adopt alternative benefit management plans to navigate the new regulatory requirements.

The takeaway

While regulatory oversight is increasing, patients should monitor their specific plan changes as companies adapt to new compliance rules. These settlements highlight the ongoing tension between market-driven drug pricing and government intervention efforts.

Further reading

For broader context on current industry oversight, see our Healthcare section.

Source note: This article includes information reported by News-Medical.

Live Poll

Do you believe current regulations on pharmacy benefit managers will lower your prescription drug costs?